Endocrine Research最新文献

{"title":"The Effects of Weight Loss and Aerobic Exercise on Cortisol and Cortisol Suppression in Postmenopausal Women with Overweight and Obesity.","authors":"Alice S Ryan, Monica C Serra, Galya Bigman, Sausan Jaber","doi":"10.1080/07435800.2024.2439408","DOIUrl":"10.1080/07435800.2024.2439408","url":null,"abstract":"<p><strong>Purpose: </strong>The goal of this study was to explore the complex relationship between obesity, dietary content, weight loss, and cortisol concentrations in postmenopausal women with overweight and obesity.</p><p><strong>Methods: </strong>Women completed basal cortisol testing, a dexamethasone suppression test (DST), DXA scan, 3-hour oral glucose tolerance test (OGTT), and food records before (<i>n</i> = 60) and a subset after 6-months of weight loss (WL; <i>n</i> = 15) or aerobic exercise training+weight loss (AEX+WL, <i>n</i> = 34).</p><p><strong>Results: </strong>At baseline, plasma cortisol concentrations decreased significantly after DST in the entire group, a 54% suppression which was associated with basal glucose. Basal glucose levels and glucose AUC from the OGTT are associated with basal cortisol levels (<i>r</i> = 0.44 and <i>r</i> = 0.29, <i>p</i> < 0.05 respectively). The intervention resulted in significant weight loss (-8%) but no significant changes in basal cortisol or changes in cortisol from basal to DST were observed.</p><p><strong>Conclusion: </strong>Additional research is necessary to better comprehend cortisol regulation in postmenopausal women particularly in response to effective weight reduction interventions.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"87-95"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Palmito-leic Acid and Nervonic Acid Hexosylceramides with Type 2 Diabetes Mellitus in a Prospective Nested Case-control Study Among Chinese Population.","authors":"Chuyi Ruan, Jun Sun, Xiaoqing Liang, Hong Huang, Mingzhi Zhang, Shaoyan Zhang","doi":"10.1080/07435800.2025.2479256","DOIUrl":"10.1080/07435800.2025.2479256","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to evaluate the associations of hexosylceramides (HexCers) and their ratio with incident type 2 diabetes mellitus (T2DM) and explore underlying mechanisms.</p><p><strong>Methods: </strong>We conducted a nested case-control study using the Suzhou chronic disease cohort including 234 T2DM cases and 468 controls, 1:2 matched on age (±2 y) and sex. HexCer(d18:1/16:1) and HexCer(d18:1/24:1) were measured by targeted UPLC-MS/MS. Multivariable conditional logistic regression was used to estimate the associations of these HexCer species and their ratio with T2DM risk.</p><p><strong>Results: </strong>After adjustment for potential confounders, compared with the lowest quartile, the highest quartile of HexCer(d18:1/24:1) was positively associated with T2DM risk (OR: 1.91; 95%CI, 1.12, 3.26; <i>P</i>-trend <0.05). The ratio of HexCer(d18:1/24:1) to HexCer(d18:1/16:1) showed a positive association with T2DM risk (OR: 1.89; 95%CI, 1.13, 3.18; <i>P</i>-trend <0.05). On the natural log scale, each SD increases in HexCer(d18:1/24:1) and its ratio to HexCer(d18:1/16:1) increased by 29% and 30%, respectively. No significant association for HexCer(d18:1/16:1) was found. Additive value of HexCer(d18:1/24:1) or HexCer(d18:1/24:1)/HexCer(d18:1/16:1) ratio for prediction of T2DM above traditional risk factors.</p><p><strong>Conclusions: </strong>HexCer(d18:1/24:1) and its ratio to HexCer(d18:1/16:1) are positively associated with incident T2DM in a community-based Chinese population. Future studies are warranted to confirm our findings.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"109-117"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Adrenocorticotropic Hormone Deficiency Associated with Sintilimab in the Treatment of Lung Adenocarcinoma: A Case Report and Literature Review.","authors":"Zehui Liu, Qiang Ma, Sha Ma, Mengru Yang, Haowei Zhang, Wenzhuo Zhu, Rui Han","doi":"10.1080/07435800.2025.2495793","DOIUrl":"https://doi.org/10.1080/07435800.2025.2495793","url":null,"abstract":"<p><p>Isolated adrenocorticotropic hormone (ACTH) deficiency, a rare condition associated with immune checkpoint inhibitors, can manifest with symptoms such as fatigue, poor appetite, dizziness, hypotension, and hyponatremia. We present a case of a 52-year-old Chinese woman with stage IB lung adenocarcinoma who developed these symptoms after 8 months of treatment with sintilimab. Laboratory tests revealed hyponatremia, low ACTH and cortisol levels, and thyrotoxicosis. Imaging studies showed a Rathke's cleft cyst in the pituitary gland but normal adrenal glands. The patient was diagnosed with isolated ACTH deficiency and thyroid dysfunction and prescribed prednisone as replacement therapy, which improved her symptoms despite persistently low ACTH levels. This case highlights the importance of early diagnosis and treatment of immune checkpoint inhibitor-related endocrine disorders and provides insights into their management to enhance clinical practice and outcomes.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause and diabetes: Interconnected associations of risk.","authors":"Carla P Rodriguez, Erin D Michos","doi":"10.1080/07435800.2025.2490891","DOIUrl":"https://doi.org/10.1080/07435800.2025.2490891","url":null,"abstract":"<p><p>Menopause is an important transition in a women's life that has been associated with a worsening cardiometabolic risk profile. Diabetes is a well-known risk factor for cardiovascular disease risk in women. Recent studies have improved the understanding of the hormonal and metabolic changes that occur during menopause, which have provided an opportunity to intervene with preventive efforts. Despite this, menopause's role and its direct (independent) relationship with cardiovascular risk factors, such as diabetes, remain largely unknown. This review highlights the inter-relationships between menopause, vasomotor symptoms, and menopausal hormone therapy with the risk of developing diabetes and outlines further knowledge gaps.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic β-Cells, Diabetes and Autophagy.","authors":"Yang Ou, Yan-Li Zhao, Heng Su","doi":"10.1080/07435800.2024.2413064","DOIUrl":"10.1080/07435800.2024.2413064","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic β-cells play a critical role in regulating plasma insulin levels and glucose metabolism balance, with their dysfunction being a key factor in the progression of diabetes. This review aims to explore the role of autophagy, a vital cellular self-maintenance process, in preserving pancreatic β-cell functionality and its implications in diabetes pathogenesis.</p><p><strong>Methods: </strong>We examine the current literature on the role of autophagy in β-cells, highlighting its function in maintaining cell structure, quantity, and function. The review also discusses the effects of both excessive and insufficient autophagy on β-cell dysfunction and glucose metabolism imbalance. Furthermore, we discuss potential therapeutic agents that modulate the autophagy pathway to influence β-cell function, providing insights into therapeutic strategies for diabetes management.</p><p><strong>Results: </strong>Autophagy acts as a self-protective mechanism within pancreatic β-cells, clearing damaged organelles and proteins to maintain cellular stability. Abnormal autophagy activity, either overactive or deficient, can disrupt β-cell function and glucose regulation, contributing to diabetes progression.</p><p><strong>Conclusion: </strong>Autophagy plays a pivotal role in maintaining pancreatic β-cell function, and its dysregulation is implicated in the development of diabetes. Targeting the autophagy pathway offers potential therapeutic strategies for diabetes management, with agents that modulate autophagy showing promise in preserving β-cell function.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"12-27"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Different TSH Suppression Levels Effect Heart Rate Variability and QT Dispersions in Patients with Differentiated Thyroid Cancer?","authors":"Semih Çelik, Ziynet Alphan Uç, Özkan Candan","doi":"10.1080/07435800.2024.2383669","DOIUrl":"10.1080/07435800.2024.2383669","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate changes in heart rate variability (HRV) and QT dispersion (QTd) in patients with differentiated thyroid cancer at different TSH suppression levels.</p><p><strong>Methods: </strong>The study included 125 DTC patients, who had been on TSH suppression treatment (TSHST) for at least 1 year. The patients were categorized into three groups: patients with TSH < 0.1 mIU/L (n:30), those with TSH 0.1 to 0.5 mIU/L (n:56), and those with TSH 0.5 to 2 mIU/L (n:39). The first two groups were classified as suppression groups, and the last as replacement (control) group. All patients underwent 12-lead electrocardiogram (ECG) recording and 24-hour rhythm holter echocardiography analysis.</p><p><strong>Results: </strong>The HRV results derived from a 24-hour rhythm holter did not exhibit any significant difference (<i>p</i> < 0.05). In dispersion evaluations, the QTd was significantly longer in the suppression groups (groups 1 and 2), than in the replacement group (group 3) (<i>p</i> < 0.001 and p:0.002, respectively). The same was found for corrected QT dispersion (QTcd) (<i>p</i> < 0.001 and p: 0.008, respectively). In multivariate linear regression analysis, TSH was found to affect QTd (β = -0.299; <i>p</i> = 0.002) and QTcd (β = -0.300; <i>p</i> = 0.002) values independently.</p><p><strong>Conclusion: </strong>In this study, it was shown that in patients with DTC receiving TSHST, QT dispersion prolonged as the TSH suppression level increased. Especially in high-risk DTC patients, evaluation of QTd may be useful in terms of evaluating cardiovascular risk and regulating TSHST level.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"28-35"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monogenic Diabetes: A Comprehensive Overview and Therapeutic Management of Subtypes of Mody.","authors":"Manisha Sharma, Kajal Maurya, Anuj Nautiyal, Havagiray R Chitme","doi":"10.1080/07435800.2024.2388606","DOIUrl":"10.1080/07435800.2024.2388606","url":null,"abstract":"<p><strong>Background: </strong>Monogenic diabetes often occurs as a result of single-gene mutations. The illness is minimally affected by environmental and behavioral factors, and it constitutes around one to five percent of all cases of diabetes.</p><p><strong>Methods: </strong>Newborn diabetes mellitus (NDM) and maturity-onset diabetes of the young (MODY) are the predominant causes of monogenic diabetes, accounting for a larger proportion of cases, while syndromic diabetes represents a smaller percentage. MODY, a group of inherited non-autoimmune diabetes mellitus disorders, is quite common. However, it remains frequently misdiagnosed despite increasing public awareness. The condition is characterized by insulin resistance, the development of diabetes at a young age (before 25 years), mild high blood sugar levels, inheritance in an autosomal dominant pattern, and the preservation of natural insulin production.</p><p><strong>Results: </strong>Currently, there are 14 distinct subtypes of MODY that have been identified. Each subtype possesses distinct characteristics in terms of their frequency, clinical symptoms, severity of diabetes, related complications, and response to medicinal interventions. Due to the clinical similarities, lack of awareness, and high expense of genetic testing, distinguishing between type I (T1D) and type II diabetes mellitus (T2D) can be challenging, resulting in misdiagnosis of this type of diabetes. As a consequence, a significant number of individuals are being deprived of adequate medical attention. Accurate diagnosis enables the utilization of novel therapeutic strategies and enhances the management of therapy in comparison to type II and type I diabetes.</p><p><strong>Conclusion: </strong>This article offers a concise overview of the clinical subtypes and characteristics of monogenic diabetes. Furthermore, this article discusses the various subtypes of MODY, as well as the process of diagnosing, managing, and treating the condition. It also addresses the difficulties encountered in detecting and treating MODY.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Investigation of Kisspeptin, Spexin and Galanin in Euthyroid Women with Hashimoto's Thyroiditis.","authors":"Ummugulsum Can, Sadinaz Akdu, Ahmet Hamdi Aktan","doi":"10.1080/07435800.2024.2384576","DOIUrl":"10.1080/07435800.2024.2384576","url":null,"abstract":"<p><strong>Objective: </strong>The hallmarks of Hashimoto's thyroiditis (HT) include the destruction of thyroid cells by leading to insulin resistance (IR), hypothyroidism, and metabolic abnormalities. Kisspeptin, spexin, and galanin control appetite and body weight (BW) to regulate metabolisms. Here, we sought to determine if galanin, kisspeptin, and spexin are linked to the pathophysiology of HT in euthyroid female individuals.</p><p><strong>Methods: </strong>Forty-five women with HT and 45 healthy control women of the same age participated in the current study. The enzyme-linked immunosorbent assay (ELISA) method was used to measure the serum levels of galanin, spexin, and kisspeptin.</p><p><strong>Results: </strong>In comparison to the controls, HT patients had significantly higher levels of kisspeptin (<i>p</i> < 0.01), galanin (<i>p</i> < 0.01), anti-thyroid peroxidase (anti-TPO) (<i>p</i> < 0.001), anti-thyroglobulin (anti-Tg) (<i>p</i> < 0.001), and body mass index (BMI) (<i>p</i> < 0.05). The two groups were comparable in terms of spexin, free triiodothyronine-3 (fT3), fT4, thyroid-stimulating hormone (TSH) levels, and homeostatic model assessment for insulin resistance (HOMA-IR). Galanin and kisspeptin were seen to have a positive correlation (<i>p</i> < 0.01; <i>r</i> = 0.786).</p><p><strong>Conclusions: </strong>Euthyroid women with HT were found to have higher levels of kisspeptin and galanin. These results imply that kisspeptin and galanin may be linked to the pathogenesis of hypothyroidism, and as a result, we believe that these markers may be beneficial in the early detection and treatment of HT patients.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"36-42"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma.","authors":"Tamara Dojcinovic, Karin Zibar Tomsic, Ivana Dora Vodanovic, Tina Dusek, Ivana Kraljevic, Anja Barac Nekic, Tanja Skoric Polovina, Nikola Knezevic, Ana Marija Alduk, Zrna Antunac Golubic, Darko Kastelan","doi":"10.1080/07435800.2024.2397561","DOIUrl":"10.1080/07435800.2024.2397561","url":null,"abstract":"<p><strong>Background: </strong>While numerous studies have explored treatment outcomes for the overall ACC patient cohort, data on the subpopulation of patients with recurrent disease are limited. Therefore, the aim of this study was to assess treatment outcomes in patients with recurrent ACC.</p><p><strong>Methods: </strong>In this retrospective study, we included 18 patients median age 49 years (42-62); 67% female) diagnosed with recurrent ENSAT stage I-III ACC who underwent either R0 (<i>n</i> = 16) or Rx (<i>n</i> = 2) surgical resection of the tumor.</p><p><strong>Results: </strong>The median time from the initial surgery to ACC recurrence was 29 months (IQR 18-50). Seven patients (39%) manifested local recurrence, while 11 patients (61%) developed distant metastases. The median follow-up duration after tumor recurrence was 32 months (IQR 25-53). Regarding the treatment of ACC recurrence, 10 patients underwent a second surgery either as an alone procedure (<i>n</i> = 4), or in combination with mitotane (<i>n</i> = 4), mitotane and chemotherapy (<i>n</i> = 1), or mitotane combined with radiotherapy (<i>n</i> = 1). The remaining patients received treatment involving chemotherapy±mitotane (<i>n</i> = 4) and locoregional therapy ±chemotherapy (<i>n</i> = 3). One patient chose not to proceed with further management and follow-up. The median PFS was 17 (95% CI 8-26) months while the median OS was not reached. In the multivariate model, increased mortality was associated with advanced age (<i>p</i> = 0.04) and a shorter interval to ACC recurrence (<i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>A significant proportion of patients with ACC recurrence experience disease progression or second recurrence, despite all treatment efforts. Nevertheless, by integrating diverse treatment modalities, many patients have the potential to attain long-term survival.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"43-49"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antithyroid Antibodies and Reproductive Parameters of Women with Hashimoto's Thyroiditis.","authors":"Rafaela Silveira Ximenes de Souza, Alessandra Quintino-Moro, Denise Engelbrecht Zantut-Wittmann, Arlete Fernandes","doi":"10.1080/07435800.2024.2405147","DOIUrl":"10.1080/07435800.2024.2405147","url":null,"abstract":"<p><strong>Objectives/introduction: </strong>To evaluate the presence and concentration of antithyroid peroxidase (TPOAb) and antithyroglobulin (TGAb) antibodies at the onset of Hashimoto's Thyroiditis (HT) and their association with disease characteristics and reproductive parameters before and after diagnosis.</p><p><strong>Methods: </strong>This is a cross-sectional study with 65 women with HT followed in an outpatient clinic. The data was collected by interviews and review of medical records. The variables were characteristics of the disease; TPOAb and TGAb measurements; pregnancies; live children; premature births; pregnancy losses and infertility. We used the chi-square or Fisher's exact tests, the Mann-Whitney test and the Spearman correlation. The significance level was set at 5%.</p><p><strong>Results: </strong>The mean age at diagnosis was 38 (SD ± 11.1) years and the duration of the disease was 7.5 (SD ± 5.3) years; 46% of the women reported infertility periods. 59/65 (90.7%) women had TPOAb and 42 (64.6%) had TGAb antibodies. Comparison between the groups with and without TPOAb or TGAb showed no differences between all variables studied. We found positive correlations between TPOAb concentration and preterm births and thyroid volume; and TGAb concentration was positively correlated with age.</p><p><strong>Conclusion: </strong>The presence of autoantibodies did not influence reproductive parameters; TPOAb concentration was correlated with premature births and thyroid volume.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"57-64"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}